@article{boisteau:hal-03595901,
TITLE = {MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer},
AUTHOR = {Boisteau, Emeric and Lespagnol, Alexandra and de Tayrac, Marie and Corre, S{\'e}bastien and Perrot, Anthony and Rioux-Leclercq, Nathalie and Martin-Lanner{\'e}e, S{\'e}verine and Artru, Pascal and Chalabreysse, Philippe and Poureau, Pierre-Guillaume and Doucet, Laurent and Coupez, Dahna and Bennouna, Jaafar and Bossard, C{\'e}line and Coriat, Romain and Beuvon, Fr{\'e}d{\'e}ric and Bauguion, Lucile and Leclair, Fran{\c c}ois and Chautard, Romain and Lecomte, Thierry and Guyetant, Serge and Desgrippes, Romain and Grasset, Denis and Lhostis, H{\'e}l{\`e}ne and Bouhier-Leporrier, Karine and Bibeau, Fr{\'e}d{\'e}ric and Edeline, Julien and Galibert, Marie-Dominique and Li{\`e}vre, Astrid},
URL = {https://hal.science/hal-03595901},
JOURNAL = {Clinics and Research in Hepatology and Gastroenterology},
PUBLISHER = {Elsevier},
VOLUME = {46},
NUMBER = {5},
PAGES = {11 p.},
YEAR = {2022},
MONTH = Feb, DOI = {10.1016/j.clinre.2022.101888},
KEYWORDS = {anti-EGFR mAb ; bevacizumab ; biomarker ; colorectal cancer ; metastasis ; miR-31-3p},
PDF = {https://hal.science/hal-03595901/file/Boisteau%20et%20al-2022-MiR-31-3p%20do%20not%20predict%20anti-EGFR%20efficacy%20in%20first-line%20therapy%20of%20RAS.pdf},
HAL_ID = {hal-03595901},
HAL_VERSION = {v1},
}